{"drugs":["Ipilimumab","Yervoy"],"mono":{"0":{"id":"929833-s-0","title":"Generic Names","mono":"Ipilimumab"},"1":{"id":"929833-s-1","title":"Dosing and Indications","sub":[{"id":"929833-s-1-4","title":"Adult Dosing","mono":"<b>Malignant melanoma, Unresectable or Metastatic:<\/b> 3 mg\/kg IV infusion over 90 minutes every 3 weeks for a total of 4 doses; permanently discontinue if treatment cannot be completed within 16 weeks "},{"id":"929833-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"929833-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment required<\/li><li><b>hepatic impairment:<\/b> no dosage adjustment required for mild hepatic impairment (total bilirubin greater than 1 to 1.5 times ULN or AST greater than ULN); no data for moderate or severe hepatic impairment<\/li><li><b>moderate immune-mediated adverse reactions or for symptomatic endocrinopathy:<\/b> withhold scheduled dose; in patients with partial or complete resolution of adverse reactions (Grade 0 to 1) AND who are receiving less than 7.5 mg of prednisone or equivalent per day, may restart at 3 mg\/kg IV every 3 weeks until administration of all 4 planned doses or 16 weeks from the first dose, whichever comes first<\/li><li><b>persistent moderate adverse reactions or inability to decrease corticosteroid dose to 7.5 mg prednisone or equivalent per day:<\/b> permanently discontinue ipilimumab<\/li><li><b>if full treatment course cannot be completed within 16 weeks:<\/b> permanently discontinue ipilimumab<\/li><li><b>colitis with abdominal pain, fever, ileus, or peritoneal signs; increase in stool frequency (7 or more from baseline), stool incontinence, need for IV hydration for more than 24 hours, gastrointestinal hemorrhage, and gastrointestinal perforation:<\/b> permanently discontinue ipilimumab<\/li><li><b>aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 5 times the ULN or total bilirubin level greater than 3 times the ULN:<\/b> permanently discontinue ipilimumab<\/li><li><b>Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations:<\/b> permanently discontinue ipilimumab<\/li><li><b>severe motor or sensory neuropathy, Guillain-Barre syndrome, or myasthenia gravis:<\/b> permanently discontinue ipilimumab<\/li><li><b>severe immune-mediated reactions involving any organ system (eg, nephritis, pneumonitis, pancreatitis, noninfectious myocarditis:<\/b> permanently discontinue ipilimumab<\/li><li><b>immune-mediated ocular disease that is unresponsive to topical immunosuppressive therapy:<\/b> permanently discontinue ipilimumab<\/li><\/ul>"},{"id":"929833-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Malignant melanoma, Unresectable or Metastatic<br\/>"}]},"2":{"id":"929833-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Ipilimumab can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation that may involve any organ system and manifest during treatment or weeks to months after discontinuation. The most common severe reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. Assess patients for signs\/symptoms of severe reactions and evaluate clinical chemistries (eg, liver function tests, thyroid function tests) at baseline and before each dose. Permanently discontinue ipilimumab and initiate systemic high-dose corticosteroid therapy for severe immune-mediated reactions.<br\/>"},"3":{"id":"929833-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929833-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"929833-s-3-10","title":"Precautions","mono":"<ul><li>immune-mediated adverse reactions, severe, life-threatening, including fatalities have been reported; monitoring recommended; permanently discontinue with severe reactions (eg, nephritis, pneumonitis, pancreatitis, noninfectious myocarditis)<\/li><li>bowel perforation, immune-mediated, severe, life-threatening, including fatalities has been reported; permanent discontinuation recommended<\/li><li>dermatitis, immune-mediated, severe, life-threatening, including fatalities has been reported; included Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration or necrotic, bullous, or hemorrhagic manifestations; monitoring recommended; permanently discontinue if severe<\/li><li>endocrinopathy (eg, hypopituitarism, adrenal insufficiency, hypogonadism), immune-mediated, severe and life-threatening has been reported; monitoring recommended; hold if symptomatic<\/li><li>enterocolitis, immune-mediated, severe, life-threatening, including fatalities has been reported; monitoring recommended; permanently discontinue if severe<\/li><li>Guillain-Barre syndrome, immune-mediated, severe, life-threatening, including fatalities has been reported; permanent discontinuation recommended<\/li><li>hemolytic anemia, immune-mediated clinically significant has been reported; permanent discontinuation recommended<\/li><li>hepatitis, immune-mediated, severe, life-threatening, including fatalities has been reported; monitoring recommended; permanently discontinue for grade 3 to 5 hepatotoxicity<\/li><li>meningitis, immune-related, has been reported; permanently discontinue if severe<\/li><li>motor or sensory neuropathy, immune-mediated, severe or life-threatening, has been reported; monitoring recommended; permanently discontinue with severe neuropathy<\/li><li>myasthenia gravis, immune-mediated, severe or life-threatening has been reported; permanent discontinuation recommended<\/li><li>nephritis, immune-related, has been reported; permanently discontinue if severe<\/li><li>ocular reaction (eg, uveitis, iritis, or episcleritis), immune-mediated, has been reported; discontinue if unresponsive to topical immunosuppressive therapy<\/li><li>pancreatitis, immune-mediated, has been reported; permanently discontinue if severe<\/li><li>pericarditis or noninfectious myocarditis, immune-related, has been reported; permanently discontinue if severe<\/li><li>pneumonitis, immune-mediated, has been reported; permanently discontinue if severe<\/li><li>Stevens-Johnson syndrome, severe, life-threatening has been reported; permanent discontinuation recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929833-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"929833-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929833-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus (any Grade, 21% to 31%; Grade 3 to 5, less than 1%), Rash (any Grade, 25% to 29%; Grade 3 to 5, 2%)<\/li><li><b>Gastrointestinal:<\/b>Colitis (any Grade, 5% to 8%; Grade 3 to 5, 3% to 5%), Diarrhea (any Grade, 32% to 37%; Grade 3 to 5, 3% to 5%)<\/li><li><b>Other:<\/b>Fatigue (any Grade, 34% to 41%; Grade 3 to 5, 5% to 7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Pericarditis (less than 1%)<\/li><li><b>Dermatologic:<\/b>Dermatitis (2% to 3%)<\/li><li><b>Endocrine metabolic:<\/b>Adrenal insufficiency (1%), Disorder of endocrine system (1% to 4%), Hypogonadism, Hypopituitarism (1% to 4%), Hypothyroidism<\/li><li><b>Gastrointestinal:<\/b>Enterocolitis (Grade 2, 5%; Grade 3 to 5, 7%), Perforation of intestine (1%)<\/li><li><b>Hematologic:<\/b>Eosinophilia (1%), Hemolytic anemia (Less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity (1% to 2%)<\/li><li><b>Musculoskeletal:<\/b>Myositis (less than 1%), Polymyositis (less than 1%)<\/li><li><b>Neurologic:<\/b>Encephalitis (less than 1%), Guillain-Barr  syndrome, Meningitis (less than 1%), Neuropathy (up to 1%), Peripheral motor neuropathy<\/li><li><b>Ophthalmic:<\/b>Iritis (Less than 1%), Orbital myositis (Less than 1%), Uveitis (Less than 1%)<\/li><li><b>Renal:<\/b>Nephritis (1%), Renal failure (less than 1%)<\/li><li><b>Respiratory:<\/b>Pneumonitis (less than 1%)<\/li><\/ul>"},"6":{"id":"929833-s-6","title":"Drug Name Info","sub":{"0":{"id":"929833-s-6-17","title":"US Trade Names","mono":"Yervoy<br\/>"},"2":{"id":"929833-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"929833-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929833-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929833-s-7","title":"Mechanism Of Action","mono":"The effect of ipilimumab (a recombinant, human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)) in the treatment of melanoma results in augmentation of T-cell activation and proliferation and an increase in T-cell responsiveness, including antitumor immune responses.<br\/>"},"8":{"id":"929833-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"929833-s-8-24","title":"Distribution","mono":"Vd: 7.21 L <br\/>"},"3":{"id":"929833-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance: 16.8 mL\/hr<\/li><li>Total body clearance, renal impairment: not substantially different compared with normal<\/li><li>Total body clearance, mild hepatic impairment: not substantially different compared with normal<\/li><\/ul>"},"4":{"id":"929833-s-8-27","title":"Elimination Half Life","mono":"15.4 days <br\/>"}}},"9":{"id":"929833-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do not shake product<\/li><li>allow vial to stand at room temperature for approximately 5 minutes prior to preparation; withdraw required volume and dilute further in NS or D5W to a final concentration of 1 to 2 mg\/mL; mix solution by gentle inversion<\/li><li>store diluted solution for no more than 24 hours under refrigeration (2 to 8 degrees C (36 to 46 degrees F)) or room temperature; discard partially used vials<\/li><li>administer by IV infusion over 90 minutes through an IV line containing a sterile, nonpyrogenic, low-protein-binding in-line filter; do not infuse with other medications; flush IV line with NS or D5W after each dose<\/li><\/ul>"},"10":{"id":"929833-s-10","title":"Monitoring","mono":"<ul><li>objective evidence of tumor regression is indicative of efficacy<\/li><li>clinical chemistries at baseline and before each dose<\/li><li>liver function tests at baseline and before each dose<\/li><li>thyroid function tests at baseline and before each dose<\/li><li>signs of immune-mediated enterocolitis (eg, blood or mucus in the stool)<\/li><li>signs of bowel perforation such as ileus<\/li><li>signs of immune-mediated endocrinopathies such as hypophysitis; imaging studies may be considered<\/li><\/ul>"},"11":{"id":"929833-s-11","title":"How Supplied","mono":"<b>Yervoy<\/b><br\/>Intravenous Solution: 5 MG\/ML<br\/>"},"13":{"id":"929833-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report severe dermatologic reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or a rash with dermal ulcerations).<\/li><li>Tell patient to immediately report signs\/symptoms of hepatotoxicity, enterocolitis, bowel perforation, pancreatitis, or nephritis.<\/li><li>Counsel patient to immediately report motor or sensory neuropathies (eg, Guillain-Barre syndrome, myasthenia gravis).<\/li><li>Instruct patient to immediately report signs\/symptoms of pneumonitis, meningitis, myocarditis, or pericarditis.<\/li><li>Drug may cause severe immune-related reactions, fatigue, diarrhea, pruritus, rash, and colitis.<\/li><li>Tell patient to immediately report signs\/symptoms of adrenal insufficiency, hypothyroidism, or hyperthyroidism.<\/li><li>Advise patient to seek immediate medical treatment for uveitis, iritis, or episcleritis.<\/li><\/ul>"}}}